Literature DB >> 22624680

Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT.

Andrew J Gilmore1, Marika Heblinski, Aaron Reynolds, Michael Kassiou, Mark Connor.   

Abstract

BACKGROUND AND
PURPOSE: N-arachidonoyl 5-HT (NA-5HT) has anti-nociceptive effects reported to be mediated by inhibitory actions at the transient receptor potential vanilloid receptor 1 (TRPV1) and fatty acid amide hydrolase (FAAH). Anandamide and N-arachidonoyl dopamine (NA-DA), endocannabinoids that activate TRPV1 or are metabolized by FAAH, also inhibit T-type calcium channels (I(Ca) ). T-type I(Ca) are expressed by many excitable cells, including neurons involved in pain detection and processing. We sought to determine whether NA-5HT also modulates T-type I(Ca) . EXPERIMENTAL APPROACH: Human recombinant T-type I(Ca) (Ca(V) 3 channels) expressed in HEK 293 cells were examined using standard whole-cell voltage-clamp electrophysiology techniques. KEY
RESULTS: NA-5HT completely inhibited Ca(V) 3 channels with a rank order of potency (pEC(50) ) of Ca(V) 3.1 (7.4) > Ca(V) 3.3 (6.8) ≥ Ca(V) 3.2 (6.6). The effects of NA-5HT were voltage-dependent, and it produced significant hyperpolarizing shifts in Ca(V) 3 steady-state inactivation relationships. NA-5HT selectively affected Ca(V) 3.3 channel kinetics. CONCLUSIONS AND IMPLICATIONS: NA-5HT increases the steady-state inactivation of Ca(V) 3 channels, reducing the number of channels available to open during depolarization. These effects occur at NA-5HT concentrations at or below those at which NA-5HT affects TRPV1 receptors and FAAH. NA-5HT is one of the most potent inhibitors of T-type I(Ca) described to date, and it is likely to exert some of its biological effects, including anti-nociception, via inhibition of these channels.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22624680      PMCID: PMC3492988          DOI: 10.1111/j.1476-5381.2012.02047.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  Cloning and expression of the human T-type channel Ca(v)3.3: insights into prepulse facilitation.

Authors:  Juan Carlos Gomora; Janet Murbartián; Juan Manuel Arias; Jung-Ha Lee; Edward Perez-Reyes
Journal:  Biophys J       Date:  2002-07       Impact factor: 4.033

2.  The Ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms.

Authors:  Gabriel E Bertolesi; Chanjuan Shi; Lindsy Elbaum; Christine Jollimore; Gabriela Rozenberg; Steven Barnes; Melanie E M Kelly
Journal:  Mol Pharmacol       Date:  2002-08       Impact factor: 4.436

Review 3.  Molecular physiology of low-voltage-activated t-type calcium channels.

Authors:  Edward Perez-Reyes
Journal:  Physiol Rev       Date:  2003-01       Impact factor: 37.312

4.  Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.

Authors:  S O Jacobsson; T Wallin; C J Fowler
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

5.  Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.

Authors:  S M Huang; T Bisogno; T J Petros; S Y Chang; P A Zavitsanos; R E Zipkin; R Sivakumar; A Coop; D Y Maeda; L De Petrocellis; S Burstein; V Di Marzo; J M Walker
Journal:  J Biol Chem       Date:  2001-08-22       Impact factor: 5.157

6.  Mechanism of arachidonic acid modulation of the T-type Ca2+ channel alpha1G.

Authors:  Karel Talavera; Mik Staes; Annelies Janssens; Guy Droogmans; Bernd Nilius
Journal:  J Gen Physiol       Date:  2004-08-16       Impact factor: 4.086

7.  Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin.

Authors:  Christopher J Fowler; Gunnar Tiger; María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; José A Ramos
Journal:  J Enzyme Inhib Med Chem       Date:  2003-06       Impact factor: 5.051

8.  A new strategy to block tumor growth by inhibiting endocannabinoid inactivation.

Authors:  Maurizio Bifulco; Chiara Laezza; Marta Valenti; Alessia Ligresti; Giuseppe Portella; Vincenzo DI Marzo
Journal:  FASEB J       Date:  2004-08-02       Impact factor: 5.191

9.  An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors.

Authors:  Susan M Huang; Tiziana Bisogno; Marcello Trevisani; Abdulmonem Al-Hayani; Luciano De Petrocellis; Filomena Fezza; Michele Tognetto; Timothy J Petros; Jocelyn F Krey; Constance J Chu; Jeffrey D Miller; Stephen N Davies; Pierangelo Geppetti; J Michael Walker; Vincenzo Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  Thalamic control of visceral nociception mediated by T-type Ca2+ channels.

Authors:  Daesoo Kim; Donghyun Park; Soonwook Choi; Sukchan Lee; Minjeong Sun; Chanki Kim; Hee-Sup Shin
Journal:  Science       Date:  2003-10-03       Impact factor: 47.728

View more
  11 in total

1.  Oxidation of endogenous N-arachidonoylserotonin by human cytochrome P450 2U1.

Authors:  Michal Siller; Sandeep Goyal; Francis K Yoshimoto; Yi Xiao; Shouzou Wei; F Peter Guengerich
Journal:  J Biol Chem       Date:  2014-02-21       Impact factor: 5.157

Review 2.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

3.  Analgesic transient receptor potential vanilloid-1-active compounds inhibit native and recombinant T-type calcium channels.

Authors:  Jeffrey R McArthur; Rocio K Finol-Urdaneta; David J Adams
Journal:  Br J Pharmacol       Date:  2019-05-16       Impact factor: 8.739

Review 4.  Modulation of T-type calcium channels by bioactive lipids.

Authors:  Jean Chemin; Magali Cazade; Philippe Lory
Journal:  Pflugers Arch       Date:  2014-02-16       Impact factor: 3.657

5.  5,6-EET potently inhibits T-type calcium channels: implication in the regulation of the vascular tone.

Authors:  Magali Cazade; Isabelle Bidaud; Pernille B Hansen; Philippe Lory; Jean Chemin
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

6.  Regulation of heterologously expressed 5-HT1B receptors coupling to potassium channels in AtT-20 cells.

Authors:  Marika Heblinski; Christopher Bladen; Mark Connor
Journal:  Br J Pharmacol       Date:  2018-12-28       Impact factor: 8.739

Review 7.  Targeting voltage-gated calcium channels in neurological and psychiatric diseases.

Authors:  Gerald W Zamponi
Journal:  Nat Rev Drug Discov       Date:  2015-11-06       Impact factor: 84.694

8.  Modulation of Recombinant Human T-Type Calcium Channels by Δ9-Tetrahydrocannabinolic Acid In Vitro.

Authors:  Somayeh Mirlohi; Chris Bladen; Marina Santiago; Mark Connor
Journal:  Cannabis Cannabinoid Res       Date:  2021-01-21

9.  Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist.

Authors:  Vinicius M Gadotti; Haitao You; Ravil R Petrov; N Daniel Berger; Philippe Diaz; Gerald W Zamponi
Journal:  Mol Pain       Date:  2013-07-01       Impact factor: 3.395

10.  Ligand determinants of fatty acid activation of the pronociceptive ion channel TRPA1.

Authors:  William John Redmond; Liuqiong Gu; Maxime Camo; Peter McIntyre; Mark Connor
Journal:  PeerJ       Date:  2014-01-28       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.